Skip to main content
Figure 1 | International Journal of Emergency Medicine

Figure 1

From: Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism

Figure 1

Kaplan-Meier curves for the principal efficacy and major bleeding outcomes in EINSTEIN PE. Incidences of (A) recurrent, symptomatic venous thromboembolism and (B) major bleeding with rivaroxaban versus enoxaparin/vitamin K antagonist [12]. From The New England Journal of Medicine: The EINSTEIN-PE Investigators, “Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism”, volume 366, pages 1287–1297. Copyright © 2012, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Back to article page

International Journal of Emergency Medicine

ISSN: 1865-1380

Contact us